Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations - Oliva, A.; Al Ismail, D.; Arcari, G.; Miele, MC; Casali, E.; Sacco, F.; Volpicelli, L.; De Angelis, M.; Mascellino, M.T.; Cancelli, F.; Raponi, G.; Carattoli, A.; et al. (Journal of Global Antimicrobial Resistance, 2023)
Keywords: Agar - therapeutic use; Carbapenems; Ceftazidime - therapeutic use; Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae KPC-variant; Fosfomycin; Fosfomycin - pharmacology; Fosfomycin - therapeutic use; Humans; Infectious Disease; Klebsiella Infections - drug therapy; Klebsiella pneumoniae; Meropenem - pharmacology; Meropenem - therapeutic use; Meropenem/vaborbactam; Synergism; Meropenem/vaborbactam; Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae KPC-variant; Carbapenems; Synergism; Fosfomycin